3,082 research outputs found
ONSET AND DURATION OF VISUAL ACUITY IMPROVEMENT AFTER DEXAMETHASONE INTRAVITREAL IMPLANT IN EYES WITH MACULAR EDEMA DUE TO RETINAL VEIN OCCLUSION
No full textPurpose: To evaluate the onset and duration of improvement in best-corrected visual acuity (BCVA) in eyes treated with dexamethasone intravitreal implant 0.7 mg (DEX implant) for macular edema after branch or central retinal vein occlusion. Methods: Post hoc analysis of data from 2 previously reported multicenter, 6-month, randomized sham-controlled clinical trials. Patients received a single DEX implant (n = 427) or sham procedure (n = 426) in the study eye. The primary endpoint was the percentage of eyes with >= 15-letter improvement in BCVA from baseline at postimplant Day 7. Results: The baseline mean BCVA was 20/80. At Day 7, 10.3% of DEX implant-treated eyes versus 4.0% of sham-treated eyes (P = 15-letter improvement in the BCVA, and 27.2% of DEX implant-treated eyes versus 10.6% of sham-treated eyes had >= 10-letter improvement (P = 15-letter BCVA gain to the last observation of >= 15-letter BCVA gain was 70 days. Conclusion: Dexamethasone intravitreal implant treatment led to improvement in BCVA compared with sham procedure as early as postimplant Day 7. The duration of >= 3-line improvement was typically 2 to 3 months
Clustering and dynamics of cytochrome bd-I complexes in the Escherichia coli plasma membrane in vivo.
No full textThe cytochrome bd-I complex of Escherichia coli is a respiratory terminal oxidase and an integral component of the cytoplasmic membrane. As with other respiratory components, the organization and dynamics of this complex in living membranes is unknown. We set out to visualize the distribution and dynamics of this complex in vivo. By exchanging cydB for cydB-gfpgcn4 on the E. coli chromosome, we produced a strain (YTL01) that expresses functional GFP-tagged cytochrome bd-I terminal oxidase complexes under wild-type genetic control. We imaged live YTL01 cells using video-rate epifluorescence and total internal reflection fluorescence (TIRF) microscopy in combination with fluorescence recovery after photobleaching (FRAP) and saw mobile spots of GFP fluorescence in plasma membranes. Numbers of GFP molecules per spot were quantified by step-wise photobleaching giving a broad distribution with a mean of approximately 76, indicating that cytochrome bd-I is concentrated in mobile patches in the E. coli plasma membrane. We hypothesize that respiration occurs in mobile membrane patches which we call 'respirazones'
Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant
No full text10.1016/j.ophtha.2011.12.028Ophthalmology11961190-1198OPHT
Biosimilars in ophthalmology: “Is there a big change on the horizon?”
No full textAshish Sharma,1 Prahalad Reddy,1 Baruch D Kuppermann,2 Bandello Francesco,3 Anat Lowenstein41Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India; 2Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, CA, USA; 3Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, Milano, Italy; 4Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Abstract: Retinal disease management has witnessed remarkable advances in posterior segment pharmacotherapy with the development of anti-VEGF molecules such as Lucentis® (ranibizumab), Eylea® (aflibercept), and off-label bevacizumab (Avastin). The US patents for ranibizumab and aflibercept will expire in 2020 (though Regeneron has indicated that it might attempt to extend its US patent to June 2023 with additional patent claims), and their European patents will expire in 2022 and 2025. Aflibercept comes off patent in 2022 in People’s Republic of China and Japan. As soon as each patent expires, biosimilar molecules could potentially come in the mainstream clinical practice as a more cost-efficient choice in the form of generic biosimilars. It is difficult to predict how significant this shift would be in terms of more cost-effective clinical management and how it will impact the care in developed and developing world. It is important for clinicians to have a clear understanding about ophthalmic biosimilars before the industry brings these molecules to the mainstream clinical use globally.Keywords: biosimilar, Razumab®, Lucentis®, Eylea®, ophthalmolog
Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: Subgroup analysis of the MEAD study
No full textBackground: Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) was approved for treatment of diabetic macular edema (DME) after demonstration of its efficacy and safety in the MEAD registration trials. We performed subgroup analysis of MEAD study results to evaluate the efficacy and safety of DEX 0.7 treatment in patients with previously treated DME. Methods: Three-year, randomized, sham-controlled phase 3 study in patients with DME, best-corrected visual acuity (BCVA) of 34.68 Early Treatment Diabetic Retinopathy Study letters (20/200.20/50 Snellen equivalent), and central retinal thickness (CRT) ≥300 μm measured by time-domain optical coherence tomography. Patients were randomized to 1 of 2 doses of DEX (0.7 mg or 0.35 mg), or to sham procedure, with retreatment no more than every 6 months. The primary endpoint was ≥15-letter gain in BCVA at study end. Average change in BCVA and CRT from baseline during the study (area-under-the-curve approach) and adverse events were also evaluated. The present subgroup analysis evaluated outcomes in patients randomized to DEX 0.7 (marketed dose) or sham based on prior treatment for DME at study entry. Results: Baseline characteristics of previously treated DEX 0.7 (n = 247) and sham (n=261) patients were similar. In the previously treated subgroup, mean number of treatments over 3 years was 4.1 for DEX 0.7 and 3.2 for sham, 21.5 % of DEX 0.7 patients versus 11.1 % of sham had ≥15-letter BCVA gain from baseline at study end (P = 0.002), mean average BCVA change from baseline was +3.2 letters with DEX 0.7 versus +1.5 letters with sham (P = 0.024), and mean average CRT change from baseline was -126.1 μm with DEX 0.7 versus -39.0 μm with sham(P < 0.001). Cataract-related adverse events were reported in 70.3 % of baseline phakic patients in the previously treated DEX 0.7 subgroup; vision gains were restored following cataract surgery. Conclusions: DEX 0.7 significantly improved visual and anatomic outcomes in patients with DME previously treated with laser, intravitreal anti-vascular endothelial growth factor, intravitreal triamcinolone acetonide, or a combination of these therapies. The safety profile of DEX 0.7 in previously treated patients was similar to its safety profile in the total study population
Cytochrome bd displays significant quinol peroxidase activity
No full textCytochrome bd is a prokaryotic terminal oxidase that catalyses the electrogenic reduction of oxygen to water using ubiquinol as electron donor. Cytochrome bd is a tri-haem integral membrane enzyme carrying a low-spin haem
BD Rhapsody WTA AbSeq Analysis
No full text<p>Dataset and codes for BD Rhapsody single cell analysis system.</p>
<p>Disclaimer: The set of codes are optimised for the associated dataset only. For detailed understanding of the analysis procesure, please refer to https://github.com/INGEN-HOPE/Single-Cell-Multi-Omics-Data-Analysis-for-BD-Rhapsody. For any kind queries, please refer to the corresponding author, or post your query on our GitHub page.</p>
Growth of number of periodic orbits of one family of skew product maps
No full textIn this article we introduce a one-parameter family of skew product (Gt)t ∈ [−ε, ε] maps exhibiting a heterodimensional cycle such that the number of isolated periodic orbits inside it has not super-exponential growth. The dynamics in the central direction of the maps Gt is described by a one-parameter family of system of iterated functions.This work is part of the PhD thesis of the author, under the supervision
of Lorenzo Diaz and Jorge Rocha. The author thanks Professors Lorenzo Diaz and Jorge Rocha, for
having proposed this topic, by the stimulating conversations, the guidance and useful suggestions.
This research was funded by by the Portuguese government through the FCT (Fundação para a
Ciência e a Tecnologia) under the project PTDC/MAT/099493/2008. The author was supported by
the grants SFRH/BD/27674/2006 and SFRH/BD/49735/2009 of FCT.info:eu-repo/semantics/publishedVersio
Community influences on E/BD student achievement
No full textNo Child Left Behind has mandated that all students reach proficiency by 2014. This mandate places special emphasis on the performance of special education students. The purpose of this study is to use social theory to understand the factors that explain the achievement of emotionally or behaviorally disordered (E/BD) students. Results suggest a differential effect of neighborhood composition on the development of social ties for Black and White E/BD students. The author argues for an increased awareness of the development of within-school social ties that integrate groups. © 2008 Corwin Press, Inc.link_to_subscribed_fulltex
Comparing the delivery to the hair bulb of two fluorescent molecules of distinct hydrophilicities by different nanoparticles and a serum formulation
No full textThe follicular route is an important drug penetration pathway in any topical application, either concerning dermatological and cosmetic skin treatments or any transdermal administration regimen. Efficient transport into follicles will depend on drug inherent properties but also on the chosen vehicle. The main study goal was to compare several systems for the delivery to the hair bulb of two fluorescent molecules of different water affinities: the hydrophobic Nile Red and the quite similar but hydrophilic Nile Blue. Three common nanoparticle types were compared in terms of encapsulation efficiency and stability: liposomes, ethosomes and polymeric nanoparticles. A liquid serum-like formulation was also developed, adjusting the final ethanol amount to the type of dye to be solubilized. Then, this formulation and the nanoparticle systems that successfully passed characterization and stability stages were further studied on their ability to reach the bulb. The serum formulation was able to deliver, both drug models, to deeper follicular regions than nanoparticles. Attending to the envisioned zone target of the follicle, the simplest approach proved to be the best choice from all the systems tested in this work. Nonetheless, nanocarriers and the inherent complexity of their manufacturing processes may be justified under very specific requirements.The author Cristiana Costa would like to acknowledge his PhD scholarship funded by Portuguese
Foundation for Science and Technology (FCT) (SFRH/BD/139522/2018). The author Bruno
Fernandes would like to acknowledge his PhD scholarship funded by FCT (SFRH/BD/131824/2017).
The author Diana Guimarães would like to acknowledge his PhD scholarship funded by FCT
(SFRH/BD/140321/2018). This study was supported by the FCT under the scope of BioTecNorte
operation (NORTE-01-0145-FEDER-000004) funded by the European Regional Development Fund
under the scope of Norte2020 – Programa Operacional Regional do Norte.info:eu-repo/semantics/publishedVersio
- …
